Xbrane Biopharma AB · OMXSTO:XBRANE

Xbrane Biopharma AB — Investor Presentation (September 2023)

29 slides from Xbrane Biopharma AB's investor presentation, September 2023

  1. Slide 1: Xbrane – a World-Leading Biosimilar Developer

    STO: XBRANE September 2023 Xbrane – a World-Leading Biosimilar Developer 1

  2. Slide 2: Important information

    Important information You must read the following before continuing. The following applies to this document and the information provided in this presentation by Xbrane Biopharma AB (publ) (the “Company”) or any person on behalf of the Company and any other material distributed or statements made in

  3. Slide 3: Xbrane addresses global health challenges by developing affordable biosimilars

    Xbrane addresses global health challenges by developing affordable biosimilars Core competence Differentiation Develop biosimilars from Patented platform technology for cell line to market approval and lowest production cost partner for sales and marketing Our purpose: Mid-term strategic focus “Enab

  4. Slide 4: Xbrane – a world-leading biosimilar developer

    Xbrane – a world-leading biosimilar developer Biosimilars – a → Biosimilar market to grow to USD 74bn by 2030 as blockbuster biologic patents expire rapidly growing market → Delivering value to society - increased accessibility and significant savings → Unique, proprietary high-yield/low-cost platfo

  5. Slide 5: Biosimilars – a rapidly growing market

    Xbrane – a world-leading biosimilar developer Biosimilars – a rapidly growing market Xbrane – a platform biosimilar developer Ximluci® – ongoing commercialisation in Europe & UK Attractive portfolio addressing USD 50bn in originator sales

  6. Slide 6: Biosimilars are follow-on products to biologics launched post patent expiry

    Biosimilars are follow-on products to biologics launched post patent expiry Pharmaceuticals Small Molecules Biologics → 60% of global market, 1-3% p.a. growth1 → 40% of global market, 10-15% p.a. growth2 → Produced via chemical synthesis → Produced via recombinant DNA technology → Followed on by ide

  7. Slide 7: Biosimilar development – faster, cost-effective & low risk

    Biosimilar development – faster, cost-effective & low risk Pre-clinical Phase I Phase III Biosimilar Likelihood of Approval1 78% 95% development process Development time Capital requirement Prob. of success Cost effectiveness 7 years +€100 million MEDIUM - HIGH Improved patient access Discovery & De

  8. Slide 8: Biosimilars rapidly claim majority of reference product market share

    Biosimilars rapidly claim majority of reference product market share Rapid biosimilars uptake leading to USD 11.5bn in global sales (2021) Favorable margins & price discounts Branded products WW annual sales Biosimilars WW annual sales → Biosimilars have in recent launches taken +70% USD million USD

  9. Slide 9: Biosimilar market expected to grow to USD 74bn by 2030

    Biosimilar market expected to grow to USD 74bn by 2030 Biologics with >USD 260bn in sales lose exclusivity by 2032 Biosimilar market to grow by 17% per year through to 2030 Estimated cumulative global annual peak sales, USD billion Global biosimilar sales, USD billion 74.0 61.5 54.5 51.6 35.4 32.9 1

  10. Slide 10: Xbrane – a platform biosimilar developer

    Xbrane – a world-leading biosimilar developer Biosimilars – a rapidly growing market Xbrane – a platform biosimilar developer Ximluci® – ongoing commercialisation in Europe & UK Attractive portfolio addressing USD 50bn in originator sales 10

  11. Slide 11: Xbrane´s modular platform technology enables significant yield advantage

    Xbrane´s modular platform technology enables significant yield advantage Proprietary host cell line library Productivity enhancing technologies Process and analytical methods + + → Library of proprietary genetically → Productivity and quality enhancing → Specific production process methods engineere

  12. Slide 12: Diverse development portfolio addressing a €53bn market

    Diverse development portfolio addressing a €53bn market Originator peak sales estimate 2026* (€ billion) Biosimilar Ximluci® BIIB801™ Xdivane™ Xtrudane™ Xdarzane™ Current portfolio candidate Branded biologics Therapeuti Ophthalmology Immunology Oncology Oncology Oncology c area Patent 2020 (US) 2024

  13. Slide 13: World-leading partnerships secured with >€80m in upcoming milestones

    World-leading partnerships secured with >€80m in upcoming milestones Product Ximluci® BIIB801TM Commercial Partner Territory Global ex. China Global Type Co-development License Upfront €7.5m USD 8m > €80m (pending) Milestones / Cost coverage €40-50m USD 80m Royalties/ profit sharing 50% EBITDA profi

  14. Slide 14: Ximluci® – ongoing commercialisation in Europe & UK

    Xbrane – a world-leading biosimilar developer Biosimilars – a rapidly growing market Xbrane – a platform biosimilar developer Ximluci® – ongoing commercialisation in Europe & UK Attractive portfolio addressing USD 50bn in originator sales 14

  15. Slide 15: Ximluci® – addressing a global underserved market

    Ximluci® – addressing a global underserved market Lucentis® used in treatment of severe eye diseases Global unmet medical need due to high drug cost 5 million affected eyes Europe & US, 50% treated Affected vision Normal vision Untreated Lucentis Eylea Avastin 0.6 2.5 2.5 1.1 0.8 13 million affected

  16. Slide 16: Ximluci® commercialisation – geographical expansion underway

    Ximluci® commercialisation – geographical expansion underway 2022 2023 2024 Regulatory process EU Production launch volume* Regulatory process US Drug substance process scale-up Pre-filled syringe development June 2023 Q2 2024 Q1 2025 Feb 2022 July 2022 March 2023 Q2 2024 FDA accepts Expected US Exp

  17. Slide 17: Ximluci® launched across 35-40% of € 5 billion ex-US market

    Ximluci® launched across 35-40% of € 5 billion ex-US market Retinal anti-VEGF sales (ex US) Comments € million Approx. € 200-300m / quarter additional market from off label Avastin1 → Ex-US market for retinal anti-VEGFs approx. € 5 billion annually → Ximluci® launched by partner STADA in approx. 35-

  18. Slide 18: Xbrane generated revenues of SEK 85 million from Ximluci H1 2023

    Xbrane generated revenues of SEK 85 million from Ximluci ® H1 2023 Xbrane sell Finished Goods to STADA… …and gets 50% of profits generated from in market sales Xbrane sales of finished goods to STADA (MSEK) Ximluci net-sales (SEK million) ILLUSTRATIVE Q1 '23 Q2 '23 Ximluci sales growth Q2 vs Q1 50.0

  19. Slide 19: Ximluci® BLA submitted to FDA with BsUFA date in April 2024

    Ximluci® BLA submitted to FDA with BsUFA date in April 2024 Retinal anti-VEGF sales (US) Comments € million Approx. USD 150m / quarter additional annual market from off label Avastin1 → US market for retinal anti-VEGFs approx. $8 billion annually → Ongoing out-licensing of Ximluci North America comm

  20. Slide 20: Attractive portfolio addressing USD 50bn in originator sales

    Xbrane – a world-leading biosimilar developer Biosimilars – a rapidly growing market Xbrane – a platform biosimilar developer Ximluci® – ongoing commercialisation in Europe & UK Attractive portfolio addressing USD 50bn in originator sales 20

  21. Slide 21: Cimzia® is a differentiated €2.1 billion TNFa inhibitor

    Cimzia® is a differentiated €2.1 billion TNFa inhibitor Cimzia® is a differentiated TNFa inhibitor Cimzia® generated €1.8 billion in sales 2021 Cimzia® sales (€ millions) Rheumatoid Arthritis (RA) Psoriasis 2500 2000 1500 1000 500 → Cimzia® is a TNFa inhibitor that reduce immune response in auto-imm

  22. Slide 22: BIIB801™ – the only publicly known Cimzia® biosimilar under development

    BIIB801™ – the only publicly known Cimzia® biosimilar under development BIIB801™ programme Partnership with Biogen with attractive terms → Out-licensing of global rights → Pilot scale process established → Xbrane responsible for and fund pre-clinical → Ongoing tech-transfer/scale-up to selected drug

  23. Slide 23: Well-positioned & commercially attractive oncology biosimilar portfolio

    Well-positioned & commercially attractive oncology biosimilar portfolio Opportunity to make a difference Oncology biosimilar portfolio €48 billion of annual reference product sales Originator Combined annual expected peak → Annual per patient cost of reference product sales >USD 100K 2028 (US) Xdiva

  24. Slide 24: Upcoming key milestones

    Upcoming key milestones  Ximluci® out-licensing of North American rights  Ximluci® FDA approval and launch  BIIB801 scale up of production process and production of clinical material triggering milestone payments as per agreement with Biogen  XdivaneTM out-licensing  Reaching positive operating

  25. Slide 25: Xbrane – a world-leading biosimilar developer

    Xbrane – a world-leading biosimilar developer Biosimilars – a → Biosimilar market to grow to USD 74bn by 2030 as blockbuster biologic patents expire rapidly growing market → Delivering value to society - increased accessibility and significant savings → Unique, proprietary high-yield/low-cost platfo

  26. Slide 26: Appendix

    Xbrane – a world-leading biosimilar developer Appendix 26

  27. Slide 27: Experienced management team and board

    Experienced management team and board Management Board of Directors Martin Åmark Siavash Bashiri David Vikström Anders Wallström Anders Tullgren Eva Nilsagård Karin Wingstrand Mats Thorén CEO COO & Head of CTO Head of Manufacturing Chairman of the Director of the Director of the Director of the Bios

  28. Slide 28: Latest financials & shareholder list

    Latest financials & shareholder list Shareholder list (31 August 2023) Financial highlights Investor Name Shares Ownership, % SEK thousands H1 2023 H1 2022 Serendipity Group 3,175,673 10.9 Bengt Göran Westman 2,294,604 7.9 Revenue 112,945 26,204 Nordnet Pensionsförsäkring 1,646,928 5.6 STADA Arzneim

  29. Slide 29: Xbrane – a World-Leading Biosimilar Developer

    STO: XBRANE Xbrane – a World-Leading Biosimilar Developer 29

Xbrane Biopharma — Investor Presentation (September 2023) on 6ix